BMS

CheckMate 7A8

NCT04075604

​

A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer

Status:

Opening Soon

26459-200.png

II

Phase

Line of Therapy.png

Neoadjuvant

Line of Therapy

Disease Stage.png

Early Cancer

Disease Stage

Target.png

Biomarker(s)

ER+, HER2-

Investigational

Product

Nivolumab, Palbociclib & Anastrozole

​

Treatment Arms

oNivolumab+Palbociclib+Anastrozole

o Palbociclib+ANZ then Nivolumab+Palbociclib+ANZ

o Palbociclib+ANZ